The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors

The β(3)‐adrenoceptor agonist mirabegron is approved for use for overactive bladder and has been purported to be useful in the treatment of obesity‐related metabolic diseases in humans, including those involving disturbances of glucose homeostasis. We investigated the effect of mirabegron on glucose...

Descripción completa

Detalles Bibliográficos
Autores principales: Dehvari, Nodi, Sato, Masaaki, Bokhari, Muhammad Hamza, Kalinovich, Anastasia, Ham, Seungmin, Gao, Jie, Nguyen, Huong T. M., Whiting, Lynda, Mukaida, Saori, Merlin, Jon, Chia, Ling Yeong, Wootten, Denise, Summers, Roger J., Evans, Bronwyn A., Bengtsson, Tore, Hutchinson, Dana S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437350/
https://www.ncbi.nlm.nih.gov/pubmed/32813332
http://dx.doi.org/10.1002/prp2.643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437350/
https://www.ncbi.nlm.nih.gov/pubmed/32813332
http://dx.doi.org/10.1002/prp2.643

Ejemplares similares